FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas

Astellas Pharma said on February 20 that the US FDA has extended its target action date by three months for its priority review of the company’s hot flash drug fezolinetant. The drug is under review for the treatment of moderate...read more